ASH Clinical News September 2017 New | Page 57

Novo Nordisk ® —
improving insurance
access for your patients
a
Novoeight ® is now preferred on
• United Healthcare formulary
• CVS Caremark formulary
Helixate ® is no longer preferred on these plans as
of January 2017.
a
Formulary status subject to change. Multiple products within the same
therapeutic class may be considered “preferred” and on the same tier. This
information should not be used to make efficacy or safety comparisons
between or among mentioned products.
8
years of clinical experience
with Novoeight ® in PTPs 1
PTPs=previously treated patients.
Talk to a Novo Nordisk Representative about Novoeight ® coverage in your area.
Visit www.Novoeightpro.com.
Indications and Usage
Novoeight ® (Antihemophilic Factor [Recombinant]) is indicated for use in adults and children with hemophilia A for control and prevention
of bleeding, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
Novoeight ® is not indicated for the treatment of von Willebrand disease.
Important Safety Information
Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight ® or its components,
including hamster proteins.
Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present
in trace amounts in the product. Should symptoms occur, discontinue Novoeight ® and administer appropriate treatment.
Development of activity-neutralizing antibodies (inhibitors) may occur. If expected plasma factor VIII activity levels are not attained,
or if bleeding is not controlled with an appropriate dose, perform an assay that measures factor VIII inhibitor concentration.
The most frequently reported adverse reactions (≥0.5%) were injection site reactions, increased hepatic enzymes, and pyrexia.
Please see brief summary of Prescribing Information on following page.
Reference: 1. Lentz SR, Misgav M, Ozelo M, et al. Results from a large multinational clinical trial (guardian ™ 1) using prophylactic treatment
with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia. 2013;19(5):691-697.
Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.
Novoeight ® is a registered trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2017 Novo Nordisk
All rights reserved.
USA17BIO00293
March 2017